Economic Observation Network In the past week, there has been significant downward pressure on stock prices, with a decline in first quarter performance and market attention on fundamentals.

Recent stock trends:
In the past 7 trading days (May 22-29), the stock price fell from $6.09 to $5.33, with a range decline of 16.06%, underperforming the Nasdaq index during the same period (+2.58%). On May 29th, it fell 4.65% in a single day and closed at $5.33. As of May 29th, the stock price has fallen below all major moving averages (5th, 10th, 20th, etc.), the KDJ indicator is in oversold territory, and the MACD indicator is running below the zero axis, indicating a weak short-term trend.

Performance and business situation:
According to the first quarter financial report for the 2026 fiscal year released by the company on May 6, 2026, there has been a decline in performance. The operating revenue for the first quarter was 30.893 million US dollars, a year-on-year decrease of 18.48%; The net profit attributable to the parent company was -15.884 million US dollars, a significant decrease of 93.94% year-on-year. Although the gross profit margin remains at a high level of 76.06%, the net profit margin is -51.42% and the return on assets (ROA) is -15.12%, indicating that the company is still in a loss making expansion phase.

Company fundamentals:
Rxsight is a medical technology company specializing in the research, development, manufacturing, and sales of light adjustable intraocular lenses (IOLs) and related ophthalmic surgical equipment Its core product aims to provide personalized vision correction for cataract patients through postoperative adjustment. The recent fluctuations in stock prices may be related to the lower than expected performance in the first quarter and changes in the overall market's risk appetite for unprofitable biotech companies.

The above content is based on publicly available information and does not constitute investment advice.